Related Experiment Video
Updated: Jan 10, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
FN-1501 Synergistically Enhances Almonertinib Efficacy in EGFR-TKI-Resistant Lung Adenocarcinoma through Ferroptosis
Sitong Feng1, Chen Peng1, Dan Zou1
1Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing 210009, China.
Introduction:
The emergence of acquired resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs) presents a significant barrier to effective treatment in lung adenocarcinoma. This study investigates the antitumor efficacy of FN-1501 and its potential synergistic interaction with Almonertinib (Alm) to combat this resistance.
Methods:
The impact of FN-1501 on lung adenocarcinoma and its synergistic effects with Almonertinib (Alm) were assessed through flow cytometry, Western blot analysis, CCK-8 assays, and clonogenic formation assays. Additionally, transcriptome analysis and network pharmacology were employed to elucidate the functional mechanisms by which FN-1501 may reverse EGFR-TKI acquired resistance.
Results:
FN-1501 demonstrated the ability to inhibit cell proliferation, induce apoptosis, and arrest the cell cycle. The combination of Alm and FN-1501 restored sensitivity in resistant cell lines. Mechanistic investigations indicated that this combination triggered ferroptosis via the FOXO1-mediated upregulation of NCOA4. In vivo experiments showed that the Alm+FN-1501 combination significantly inhibited tumor growth compared to either treatment alone.
Discussion:
These results provide compelling evidence that targeting ferroptosis pathways could be a viable approach to overcoming resistance to EGFR-TKIs. The FOXO1/NCOA4 axis emerges as a critical component in this process, enhancing our understanding of the mechanisms underlying resistance. While these findings are promising, further research is needed to evaluate toxicity, pharmacokinetics, and the applicability of this strategy in a broader context of resistance. Identifying predictive biomarkers could help refine patient selection for this treatment approach.
Conclusion:
FN-1501 exhibits significant antitumor activity and, when combined with Alm, effectively reverses EGFR-TKI resistance by inducing ferroptosis, highlighting its potential for clinical application.
Insights
FN-1501 combined with Almonertinib overcomes acquired resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in lung adenocarcinoma by inducing ferroptosis. This combination shows significant antitumor effects and potential for clinical application.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Acquired resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs) is a major challenge in treating lung adenocarcinoma.
- Investigating novel therapeutic strategies to overcome this resistance is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the antitumor efficacy of FN-1501 as a monotherapy and in combination with Almonertinib (Alm).
- To elucidate the mechanisms by which FN-1501 and Alm overcome acquired EGFR-TKI resistance, focusing on ferroptosis induction.
Main Methods:
- Cell proliferation, apoptosis, and cell cycle arrest were assessed using CCK-8, flow cytometry, and clonogenic assays.
- Western blot, transcriptome analysis, and network pharmacology were used to explore underlying molecular mechanisms.
- In vivo studies evaluated the efficacy of the combination therapy in inhibiting tumor growth.
Main Results:
- FN-1501 demonstrated significant antitumor activity, inhibiting proliferation and inducing apoptosis.
- The combination of Almonertinib and FN-1501 restored sensitivity in resistant lung adenocarcinoma cell lines.
- Mechanistic studies revealed that the combination therapy triggers ferroptosis via the FOXO1/NCOA4 axis, leading to significant tumor growth inhibition in vivo.
Conclusions:
- Targeting ferroptosis pathways, particularly the FOXO1/NCOA4 axis, is a promising strategy to overcome acquired resistance to EGFR-TKIs.
- The combination of Almonertinib and FN-1501 shows potential for clinical application in treating resistant lung adenocarcinoma.
- Further research is warranted to explore toxicity, pharmacokinetics, and identify predictive biomarkers for patient selection.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...